MetaCap

Aprea Therapeutics (APRE) vs Imunon (IMNN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Imunon is the larger company by market cap ($3.5 million vs $3.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

APRE-62.15%IMNN-53.03%
+13%-26%-66%
Oct 7, 20261 yearNov 20, 2026
APRE-62.11%IMNN-50.42%
+18%-24%-66%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

APRE versus IMNN key metrics
MetricAPREIMNN
Share price$0.229$0.5355
Market cap$3.25M$3.47M
1-day change-53.56%-5.22%
EPS (TTM)$-0.57$-3.31
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-12.60M$-14.50M
52-week high$1.49$4.35
52-week low$0.2036$0.50
Distance from 52-week high-84.63%-87.69%
Analyst consensusnonestrong_buy
Avg. price target upside+1528.82%+3074.60%
Average volume388.67K150.49K
Shares outstanding14.19M6.49M
Employees820
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Aprea Therapeutics

APRE stock →

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

About Imunon

IMNN stock →

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees

APRE vs IMNN FAQ

Which is bigger, Aprea Therapeutics or Imunon?

Imunon (IMNN) is larger, with a market capitalization of $3.47M compared with $3.25M for Aprea Therapeutics (APRE).

Are Aprea Therapeutics and Imunon in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons